Celltrion Inc

Celltrion Inc. is a South Korean biopharmaceutical business headquartered in Incheon. Celltrion Healthcare is responsible for the global marketing, sales, and distribution of Celltrion's biological therapies. The company's medicines are manufactured in mammalian cell culture facilities that have been designed and built to meet the cGMP criteria of the US FDA and the GMP standards of the European Medicines Agency.

Celltrion of South Korea has recently earned a name for itself with biosimilar copies of big-name bestsellers, and it aims to add even more in the future years. Celltrion is spending big on an ambitious R&D and manufacturing expansion at its existing South Korean headquarters to get there. Celltrion, a significant force in the Korean pharmaceutical business, did the unthinkable by launching the world's first "antibody biosimilar" from a country with a relatively underdeveloped pharmaceutical sector. The company has successfully pioneered various unexplored areas, and it expects to continue its expansion as a global biopharmaceutical company with unique methods to small molecule medications and new companies such as the Ubiquitous-healthcare platform business.

Celltrion is an abbreviation for "cell" in body and "Triones," a guiding star also known as the Big Dipper. The company's name expresses the desire to enhance human health and welfare by being a "guiding star" in the bio industry. Celltrion Healthcare works tirelessly to realize its goal of "rewriting the world's bio-history." It works to make the world a better and healthier place by emphasizing the importance of coexistence and prosperity.

Founded: 1991
Headquarters: Incheon, South Korea
Website: https://www.celltrion.com/